administered a combination of platinum and etoposide—a small‐cell‐directed chemotherapy regimen—and the EGFR TKI Osimertinib to patients with EGFR/TP53/RB1‐mutant lung adenocarcinoma in a clinical trial [289]. The gene discussed is TP53; the disease is lung adenocarcinoma.